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Abstract
Optimal management of renal artery stenosis has continued to remain elusive. The previous
non randomized studies and registry data suggested a benefit of renal artery stenting. However,
the recently completed randomized studies comparing renal stenting to medical management
failed to show any benefit. These studies had some flaws in their design and methodology. In
an appropriately selected patient population renal artery stenting may have a role. In addition,
there might be some role of adjunctive therapies like antiplatelet medications and embolic
protection. This review summarizes the current literature on this controversial topic. (Cardiol J
2013; 20, 1: 11–16)
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Introduction
Renal artery stenosis (RAS) affects approxi-
mately 5% of the 50 million people with hyperten-
sion in Unites States. In patients older than 50 years
RAS may account for up to 15% of chronic renal
failure and 20% with end stage renal disease. The
prevalence of RAS of greater than 60% luminal nar-
rowing is approximately 7% in patients who are
65 years of age or older [1]. Most cases of RAS result
from arteriosclerosis of the renal artery. In minor-
ity, especially in younger subjects it may result from
fibromuscular dysplasia. In one study of the Medi-
care population, the prevalence of symptomatic athe-
rosclerotic RAS was 0.5% overall and approxima-
tely 5.5% among those with chronic kidney disease
[2]. In another study of elderly population involv-
ing duplex ultrasonography, the prevalence was 7%
[3]. The prevalence of the atherosclerotic RAS in-
creases with age, particularly in patients who suf-
fer from diabetes, hyperlipidemia, peripheral vas-
cular disease, coronary disease and hypertension.
Caps et al. [4] found that 50% of patients with RAS
greater than 60% progressed at the follow-up of
33 months. However, only 3% progressed to complete
occlusion in this study. There is a close association
between severity of RAS and renal atrophy leading
to ischemic nephropathy [4, 5].
Fibromuscular dysplasia
Fibromuscular dysplasia accounts for less than
10% of all cases of RAS. It is usually seen in young
(< 40 years) females and involves the mid or distal
segments of the renal artery. Fibromuscular dys-
plasia can be successfully treated with angioplasty.
In a study of Tegtmeyer et al. [6] percutaneous
transluminal renal angioplasty (PTRA) was used to
treat 66 patients with 85 renal artery stenoses due
to fibromuscular dysplasia. The initial success rate
for the procedure was 100%. The recurrence rates
were 8% of lesions and 10% of patients. Cumula-
tive patency rate predicted for 10 years was 87.07%.
The mean systolic pressure decreased by 52 mm
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Hg and the mean diastolic pressure decreased by
35 mm Hg in response to treatment. Approximate-
ly, 40% of the patients were cured, 60% were clas-
sified as improved, and only 1 (2%) did not respond
to PTRA. Renal function was improved in 86% of
the patients and stabilized in 14% of the patients.
The optimal medical management for the ath-
erosclerotic RAS (ARAS) continues to remain con-
troversial. Refractory hypertension and end stage
renal disease may occur in patients with advanced
RAS but the incidence of these outcomes was re-
ported to be low in patients who are treated medi-
cally [4, 7, 8]. Except for patients with renal artery
occlusion there seems to be a poor correlation be-
tween severity of the stenosis and the renal func-
tion [9, 10].
Atherosclerotic renal artery stenosis
and cardiovascular outcomes
Patients suffering from ARAS are at a higher
risk of cardiovascular events. In one study the rate
of chronic kidney disease was 25% vs. 2% in pa-
tients with and without ARAS. Similarly, the inci-
dence of coronary artery disease was 67% vs. 25%,
stroke was 37% vs. 12% and that of peripheral vas-
cular disease was 56% vs. 13%, respectively [2].
Renal insufficiency in patients with ARAS has been
associated with decreased survival [11]. The long-
-term cardiovascular outcomes following coronary
angiographies were significantly higher in patients
with concomitant ARAS than those without [12, 13].
ARAS has also been associated with left ventricular
dysfunction and congestive heart failure [14, 15]. Con-
versely, improvement in renal function in patients
with ARAS following PTRA has been reported to
improve survival as well as quality of life [16–18].
Current evidence on the role of PTRA
and stenting in patients with ARAS
As has been previously alluded to, the role of
renal angioplasty and stenting has remained con-
troversial. Leertouwer et al. [19] performed meta-
analysis on the studies of renal arterial stent place-
ment (14 articles, 678 patients) and renal PTA
(10 articles, 644 patients) published up to August 1998.
A random-effects model was used to pool the data.
The mean follow-up was approximately 17–19
months. In the PTRA alone arm of this study tech-
nical success was achieved in 77% of patients. Hy-
pertension was cured in10% and improved in 53%
of the patients. Renal insufficiency stabilized in 41%
and improved in 38% patients. In the renal stent arm
of the meta-analysis technical success rate was 98%.
Hypertension improved in 49% and was cured in 20%.
Renal insufficiency improved in 30% and stabilized in
38% of these patients. The restenosis (> 50% at
6 months) was 26% in PTRA alone group vs. 17%
in the renal artery stenting group. Interestingly the
cure rate for hypertension was higher and the im-
provement rate for renal function was lower after
stent placement than after renal PTA (20% vs. 10%
and 30% vs. 38%, respectively; p < 0.001).
Stenting vs. medical management
Three small randomized, controlled trials
showed no benefit of renal stenting combined with
medical management over medical management
alone [20–22]. A significant improvement in blood
pressure (BP) however was noted in the renal stent-
ing arm of one of the studies including patients with
bilateral stenosis [21]. However, these earlier tri-
als was that they were small sized and thus under-
powered to detect any clinically significant benefit.
These trials evaluated surrogate end points like BP,
creatinine and reduction in number of hypertensive
medications. The medical regimens designed were
inadequate and inconsistent. They enrolled patients
with < 50% stenosis and the crossover between the
treatment arms was allowed but analysis was done
on the basis of intention to treat. There were no
standardized core laboratories for the assessment
of renal angiograms. The biggest flaw of these small
trials was that they lacked the analysis on cardio-
vascular outcomes.
Recent randomized trials comparing
stenting plus medical therapy
with medical therapy alone
Three recently published randomized con-
trolled trials no benefit of medical therapy with
stenting when compared to medical therapy alone
[23–25].
NITER trial
Nephropathy Ischemic Therapy trial [23] in-
cluded the 52 elderly patients with > 70% stenos-
is. The diagnosis in each of these patients was ob-
tained by Doppler and confirmed by magnetic reso-
nance angiography (MRA). Endpoints of this study
included death, initiation on dialysis, decline in es-
timated glomerular filtration rate (eGFR) by 20%
and hospitalization. There was no benefit of pre-
served renal function or improved survival observed
when stenting was added to medical management.
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However, there were some serious limitations in
the design of this study. This was a small study in
which the diagnosis of RAS was primarily made with
the Doppler/MRA. The medical therapy was not
precisely defined. There was crossover allowed in
the study and the study lacked a core laboratory ad-
judication.
STAR trial
Stenting in Renal Dysfunction Caused by Athe-
rosclerotic Renal Artery (STAR) trial [24] was
a multi centric, randomized clinical trial conducted
at 10 European centers including, 140 patients with
eGFR < 80 mL/min/1.73 m2 and a renal stenosis of
greater than 50%. The primary endpoint was great-
er than a 20% decline in eGFR. Seventy six patients
were randomized to medical treatment only and
64 patients to both medical treatment and stenting.
Of the 64 patients randomized to the stent only
46 patients actually received the stent. Sixteen percent
of patients in medical treatment alone arm and 10%
in medical treatment plus stent arm reached the end
point of > 20% decline in eGFR (p = NS). The
groups did not differ in BP control or the compos-
ite end point of decline in renal function and sur-
vival. There were certain inherent problems with
the design of this study. The study groups were
small to begin with. The follow-up was short and
the study had no core laboratory adjudication. Ap-
proximately, 28% of the patients who were rando-
mized to the stent arm did not receive the stent.
Medical treatment was poorly defined. The authors
of the STAR trial concluded that their results are
compatible with both efficacy and harm and there-
fore were inconclusive.
ASTRAL trial
Angioplasty and Stenting for Renal Artery Le-
sions [25] was a multi centric randomized trial con-
ducted in European centers in which 806 patients
with at least one RAS > 50% and whose physicians
were uncertain whether early revascularization was
clinically indicated were randomized to stenting and
medical therapy vs. medical therapy alone. The pri-
mary end point which was defined as a change in
renal function measured by the reciprocal of the
serum creatinine level, was not significantly differ-
ent between the two study groups at 5 years of fol-
low-up. The secondary outcomes, including decline
in BP and rates of myocardial infarctions, cere-
brovascular events, congestive heart failure or risk
adjusted mortality were similar in both treatment
arms. As was seen with earlier randomized stud-
ies, the ASTRAL trial also had certain important
limitations. The study included many patients with-
out clinically significant lesions who would not ben-
efit from renal stenting. Also, this trial was under-
powered to detect the difference in cardiovascular
events. Almost a quarter of patients who were ran-
domized to stent arm underwent angioplasty only
without a stent placement. Twelve percent of the
patients who received a stent had a residual steno-
sis > 50%, and 7% of the patients in the stent arm
had angioplasty only. There were high complication
rates and the medical treatment was not well de-
fined. There were 3 procedure related deaths re-
ported in this study.
Therefore, 3 of these trials had serious flaws
in their design. None of the studies were designed
to have an adequate power to evaluate a composite
end point of cardiovascular outcomes. All only eval-
uated the surrogate endpoints. The major issue with
these trials was that the patients with clinically sig-
nificant lesions who would benefit from renal stent-
ing were not included in the studies. The medical
management was either imprecisely defined or in-
adequate in each of the trials. Thus, the best treat-
ment option for the treatment of RAS continues to
remain elusive [26].
The Cardiovascular Outcomes in Renal Athero-
sclerotic Lesions (CORAL) [27] study is a large
multi centric, randomized trial which is expected
to be completed in 2012. The study includes the
patients, with greater than 60% stenosis and recei-
ving at least two anti-hypertensive medications, and
with creatinine < 3 mg/dL. This trial is comparing
renal stenting vs. optimal medical management, and
is expected to help us understand whether renal
stenting improves renal function, patient survival,
cardiovascular outcomes and quality of life. There
are separate core laboratories which will analyze all
angiograms, allocation of medical treatment, labo-
ratory work up and other imaging tests. Pending the
results of the CORAL study, the best option for the
treatment of RAS remains unclear. Another ongo-
ing trial is looking at the effect of stenting with op-
timal medical management vs. medical management
alone on the renal function at 12 months following
stenting. Another study RADAR is currently going
on and is looking at the effect of renal artery stent-
ing when compared to medical therapy alone [28].
Current practice and guidelines
According to the current guidelines on peri-
pheral artery disease [29], revascularization in pa-
tients suffering from RAS and recurrent episodes
of congestive heart failure have received a class I
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indication. They have recommended renal revascu-
larization as a class IIa indication in patients with
(i) global renal ischemia, (ii) progressive chronic
kidney disease, (iii) unstable angina (worsening, or
resistant), (iv) hypertension that is worsening, re-
sistant, malignant or associated with an unexplained
unilateral small kidney or in patients who cannot
tolerate antihypertensive medications.
Future direction
Clinical significance of a hemodynamically
significant stenosis
RAS causes a drop in BP distal to the site of
occlusion. In a unilateral stenosis this drop in pres-
sure may act as a stimulus for the activation of re-
nin-angiotensin-aldosterone axis. The contra lateral
kidney responds by pressure natreuresis in order
to lower BP. This fall in BP further decreases the
BP and perfusion distal to the stenotic lesion in the
affected kidney [30]. This drop in BP is important
for the development and perpetuation of renovas-
cular hypertension. Thus what constitutes a hemo-
dynamically significant lesion is important for an
interventionalist to know because these hemody-
namically significant lesions are more likely to re-
spond to the renal angioplasty and stenting. De
Bruyne et al. [30] obtained trans-stenotic pressure
gradient before and after unilateral stenting in
15 patients. Stenosis severity of was expressed as the
ratio of distal pressure (PD) to the aortic pressure
(PA). Baloon inflation was adjusted so as to create
60% of stenosis with a controlled pressure gradi-
ent of 1 to 0.5 between the aorta (PA) and the distal
part of the renal artery (PD) with each step lasting
10 min. The plasma renin concentrations were
measured at the end of each step in the aorta and
both renal veins. In this study they found that when
the PD /PA ratio is greater than 0.9 there was no sig-
nificant change in the levels of renin concentrations
observed. Thus, a lesion with a PD/PA ratio of great-
er than 0.9 is unlikely to give rise to renovascular
hypertension. However, a PD/PA ratio of less than
0.9 resulted in a significant increase in the renin
levels as measured from the renal vein sampling of
the stenotic kidney. The renin levels returned to
baseline when the stenosis was relieved. Interest-
ingly plasma renin concentrations also increased in
the contralateral non stenotic kidneys. Evaluations
for hemodynamically significant lesions in patients
with renal stenosis may help improve proper patient
selection for the angioplasty and stenting. In a re-
cent study Lessar et al. [31] the role of renal trans-
lesional pressure gradient and intravascular ultra-
sound in predicting the improvement in hyperten-
sion following renal artery stenting in patients with
RAS was evaluated. In this study 62 patients had
translesional pressure gradient, resting and hyper-
emic systolic gradient (HSG), fractional flow re-
serve, and mean gradient measured by a guidewire
and angiographic parameters including minimum
lumen area and diameter, area stenosis, and diame-
ter stenosis measured quantitatively by intravas-
cular ultrasound. HSG ≥ 21 mm Hg was found to
be an independent predictor of improvement in hy-
pertension following renal stenting, with decrease
in the number of anti hypertensive medication in
the group with HSG ≥ 21 mm Hg.
Role of distal embolization and embolic
protection devices during renal stenting
and angioplasty
Renal stenting has been reported to result in
the peri-procedural loss of renal function in some
patients [32–37]. There are multiple factors that
might be responsible for this reported periproce-
dural loss of renal function but the most likely be-
ing distal embolization. Distal embolization is very
common during renal stenting and angioplasty and
as such the interest in the protected renal stenting
has evolved. Earlier studies on the use of distal
protection during renal stenting reported better
outcomes. However, the only prospective randomi-
zed controlled trial evaluating role of distal protec-
tion with and without abciximab in patient undergo-
ing renal stenting (RESIST) [35] failed to show any
benefit of an embolic protection alone. There could
have been multiple reasons for the failure of embo-
lic protection device in preserving renal function in-
cluding incomplete protection, incomplete apposition
of the device to the vessel wall, embolization prior
to deployement of the device and smaller size of the
embolized material. Most importantly, RESIST study
was underpowered due to its small size to detect any
benefit of embolic protection.
Role of antiplatelet therapy during
renal artery stenting and angioplasty
In the RESIST [35] trail, Cooper et al. [35] re-
ports the effects of renal stenting with and without
distal protection device as well as with and without
abciximab on the percent change in MDRD GFR at
1 month when compared to the baseline. In this 2X2
factorial designed study almost 100 patients were
randomized to either stenting alone, stenting with
embolic protection, stenting with abciximab and
stenting with both abciximab and embolic protec-
tion. The angiographic analysis, the analysis of fil-
15
Khalil Kanjwal, Vincent M. Figueredo, Renal artery stenting
www.cardiologyjournal.org
ter contents and the analysis of renal function were
performed at 3 separate core laboratories respec-
tively, with analyzers blinded to both the treatment
and clinical outcomes. Stenting alone, stenting with
embolic protection and stenting with abciximab
were associated with decline in renal function at
1 month. However, an unanticipated interaction was
observed between abciximab and embolic protec-
tion device with improvement in renal function ob-
served in the group randomized to renal stenting
with both abciximab and embolic protection.
Further subgroup analysis of the RESIST trial
demonstrated that the embolized material captured
was predominantly platelet rich suggesting platelet
activation is common during renal stenting [38, 39].
In an another subgroup analysis on the use of
thienopyridines in the RESIST trial it was shown
that the thienopyridines significantly reduced em-
bolization of platelet rich emboli [39]. Use of
thienopyridines in subgroup of patients who were
randomized to both embolic protection and abci-
ximab was associated with no distal embolization.
Thus, the use of thienopyridines may be additive
or even synergestic when combined with use of
abciximab [39]. However thienopyridine use was
not associated with improvement in renal function
at 1 month despite reducing distal embolization.
This might have been possibly because the use of
thienopyridine antiplatelet was not randomly allo-
cated rather was clinically prescribed. Further, the
study was not powered enough to detect the
thienopyridine effect [39].
Controversies in the diagnosis
of renal artery stenosis
The diagnosis of RAS has been as controver-
sial as has been the optimal management of the
RAS. Renal angiography is the gold standard for
diagnosis of the renal stenosis. However, this pro-
cedure is invasive with risks of adverse events in-
cluding vessel injury and contrast nephropathy. It
is crucial for an interventionalist to know the anat-
omy and status of the renal artery before the pa-
tient is taken for angioplasty. The pretest probabil-
ity of RAS plays an important role in deciding about
the choice of diagnostic modality. Although the pre-
valance of renal stenosis in general hypertensive
population is 1–5%, in patients who have a high
pretest probability of having RAS, the prevalance
may be as high as 40% in some patients [40, 41].
Besides renal angiography, the other diagnostic
tests available for the diagnosis of the RAS include,
duplex ultrasonography, computed tomographic
angiography (CTA), MRA, captopril scinitigraphy and
captopril test. In a meta-analysis by Boudewijn et al.
[41] it was found that both CTA and MRA were equal-
ly good in the diagnosis of the RAS (both had a area
under ROC curve of 0.99). Both, were found to be
superior to duplex ultrasound and the captopril scin-
tigraphy (p = 0.02). Duplex ultrasonography and
captopril scintigraphy were both superior to the cap-
topril test (p = 0.01). Renal angiography was used
as a gold standard for the diagnosis of RAS in each of
the studies included in the meta-analysis. The diag-
nosis of the RAS can be made with the use of duplex
ultrasonography but if the results of the ultrasono-
graphy are inconclusive or technically limited, MRA
or CTA should be used [28].
Conclusions
The diagnosis as well as the optimal medical
management of the patient suffering from RAS con-
tinues to be controversial. In future we expect
CORAL and RADAR trials might help answer many
questions which earlier trials failed to do.
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